deltatrials
Active Not Recruiting PHASE2 INTERVENTIONAL 2-arm NCT04950075

Study of INBRX-109 in Conventional Chondrosarcoma (ChonDRAgon)

A Randomized, Blinded, Placebo-controlled, Phase 2 Study of INBRX-109 in Unresectable or Metastatic Conventional Chondrosarcoma

Sponsor: Inhibrx Biosciences, Inc

Conditions Conventional Chondrosarcoma
Interventions INBRX-109 Placebo
Updated 31 times since 2021 Last updated: Jan 7, 2026 Started: Sep 23, 2021 Primary completion: Sep 30, 2025 Completion: Dec 31, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Conventional Chondrosarcoma and is currently ongoing. Inhibrx Biosciences, Inc leads this study, which shows 31 recorded versions since 2021 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Sep 2021 – ~Nov 2021 · 2 months · monthly snapshot~Nov 2021 – ~Jan 2022 · 2 months · monthly snapshot~Jan 2022 – ~Feb 2022 · 31 days · monthly snapshot~Feb 2022 – ~Mar 2022 · 28 days · monthly snapshot~Mar 2022 – ~Apr 2022 · 31 days · monthly snapshot~Apr 2022 – ~Jun 2022 · 2 months · monthly snapshot~Jun 2022 – ~Jul 2022 · 30 days · monthly snapshot~Jul 2022 – ~Sep 2022 · 2 months · monthly snapshot~Sep 2022 – ~Oct 2022 · 30 days · monthly snapshot~Oct 2022 – ~Dec 2022 · 2 months · monthly snapshot~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshot~Jan 2023 – ~Feb 2023 · 31 days · monthly snapshot~Feb 2023 – ~Apr 2023 · 59 days · monthly snapshot~Apr 2023 – ~Jun 2023 · 2 months · monthly snapshot~Jun 2023 – ~Jul 2023 · 30 days · monthly snapshot~Jul 2023 – ~Sep 2023 · 2 months · monthly snapshot~Sep 2023 – ~Oct 2023 · 30 days · monthly snapshot~Oct 2023 – ~Nov 2023 · 31 days · monthly snapshot~Nov 2023 – ~Dec 2023 · 30 days · monthly snapshot~Dec 2023 – ~Jan 2024 · 31 days · monthly snapshot~Jan 2024 – ~Feb 2024 · 31 days · monthly snapshot~Feb 2024 – ~Mar 2024 · 29 days · monthly snapshot~Mar 2024 – ~May 2024 · 2 months · monthly snapshot~May 2024 – ~Jun 2024 · 31 days · monthly snapshot~Jun 2024 – ~Jul 2024 · 30 days · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Nov 2024 · 2 months · monthly snapshot~Nov 2024 – ~Feb 2025 · 3 months · monthly snapshot~Feb 2025 – ~Sep 2025 · 7 months · monthly snapshot~Sep 2025 – ~Feb 2026 · 5 months · monthly snapshot~Feb 2026 – present · 7 months · monthly snapshot

Change History

31 versions recorded

  1. Feb 2026 — Present [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  2. Sep 2025 — Feb 2026 [monthly]

    Recruiting PHASE2

  3. Feb 2025 — Sep 2025 [monthly]

    Recruiting PHASE2

  4. Nov 2024 — Feb 2025 [monthly]

    Recruiting PHASE2

  5. Sep 2024 — Nov 2024 [monthly]

    Recruiting PHASE2

▶ Show 26 earlier versions

  1. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE2

  2. Jun 2024 — Jul 2024 [monthly]

    Recruiting PHASE2

  3. May 2024 — Jun 2024 [monthly]

    Recruiting PHASE2

  4. Mar 2024 — May 2024 [monthly]

    Recruiting PHASE2

  5. Feb 2024 — Mar 2024 [monthly]

    Recruiting PHASE2

  6. Jan 2024 — Feb 2024 [monthly]

    Recruiting PHASE2

  7. Dec 2023 — Jan 2024 [monthly]

    Recruiting PHASE2

  8. Nov 2023 — Dec 2023 [monthly]

    Recruiting PHASE2

  9. Oct 2023 — Nov 2023 [monthly]

    Recruiting PHASE2

  10. Sep 2023 — Oct 2023 [monthly]

    Recruiting PHASE2

  11. Jul 2023 — Sep 2023 [monthly]

    Recruiting PHASE2

  12. Jun 2023 — Jul 2023 [monthly]

    Recruiting PHASE2

  13. Apr 2023 — Jun 2023 [monthly]

    Recruiting PHASE2

  14. Feb 2023 — Apr 2023 [monthly]

    Recruiting PHASE2

  15. Jan 2023 — Feb 2023 [monthly]

    Recruiting PHASE2

  16. Dec 2022 — Jan 2023 [monthly]

    Recruiting PHASE2

  17. Oct 2022 — Dec 2022 [monthly]

    Recruiting PHASE2

  18. Sep 2022 — Oct 2022 [monthly]

    Recruiting PHASE2

  19. Jul 2022 — Sep 2022 [monthly]

    Recruiting PHASE2

  20. Jun 2022 — Jul 2022 [monthly]

    Recruiting PHASE2

  21. Apr 2022 — Jun 2022 [monthly]

    Recruiting PHASE2

  22. Mar 2022 — Apr 2022 [monthly]

    Recruiting PHASE2

  23. Feb 2022 — Mar 2022 [monthly]

    Recruiting PHASE2

  24. Jan 2022 — Feb 2022 [monthly]

    Recruiting PHASE2

  25. Nov 2021 — Jan 2022 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  26. Sep 2021 — Nov 2021 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Inhibrx Biosciences, Inc
Data source: Inhibrx Biosciences, Inc

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Adelaide, Australia , Ann Arbor, United States , Baltimore, United States , Barcelona, Spain , Berlin, Germany , Beverly Hills, United States , Bologna, Italy , Bordeaux, France , Boston, United States , Camperdown, Australia and 52 more locations